These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23690159)

  • 1. Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.
    Tristão FS; Amar M; Latrous I; Del-Bel EA; Prediger RD; Raisman-Vozari R
    Neurotox Res; 2014 Jan; 25(1):24-32. PubMed ID: 23690159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Aguiar AS; Tristão FS; Amar M; Chevarin C; Lanfumey L; Mongeau R; Corti O; Prediger RD; Raisman-Vozari R
    Neurotox Res; 2013 Aug; 24(2):280-7. PubMed ID: 23588969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling.
    Fujita A; Fujita Y; Pu Y; Chang L; Hashimoto K
    Psychopharmacology (Berl); 2020 Jan; 237(1):83-92. PubMed ID: 31418048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.
    Kadar H; Le Douaron G; Amar M; Ferrié L; Figadère B; Touboul D; Brunelle A; Raisman-Vozari R
    Neurotox Res; 2014 Jan; 25(1):135-45. PubMed ID: 24347373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.
    Prediger RD; Aguiar AS; Rojas-Mayorquin AE; Figueiredo CP; Matheus FC; Ginestet L; Chevarin C; Bel ED; Mongeau R; Hamon M; Lanfumey L; Raisman-Vozari R
    Neurotox Res; 2010 Feb; 17(2):114-29. PubMed ID: 19629612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
    Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
    J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase.
    Zhang J; Graham DG; Montine TJ; Ho YS
    J Neuropathol Exp Neurol; 2000 Jan; 59(1):53-61. PubMed ID: 10744035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson's Disease via Peroxisome Proliferator-Activated Receptorα.
    Prorok T; Jana M; Patel D; Pahan K
    Neurochem Res; 2019 Apr; 44(4):751-762. PubMed ID: 30612307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and evaluation of mucoadhesive microemulsion for neuroprotective effect of ibuprofen following intranasal route in the MPTP mice model.
    Mandal S; Mandal SD; Chuttani K; Sawant KK; Subudhi BB
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1340-50. PubMed ID: 26710671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.